Dopamine supersensitivity psychosis
Dopamine supersensitivity psychosis is a hypothesis that attempts to explain the phenomenon in which
Mechanism
Dopamine supersensitivity psychosis may occur due to
The result is dopamine supersensitivity. It is thought that the psychotic symptoms within
Tardive dyskinesia, a type of rare movement disorder that can be caused by antipsychotics, may also be caused by dopamine receptor sensitization. This may explain why, for people with tardive dyskinesia, increasing the dose of the antipsychotic may temporarily improve symptoms.[5]
Diagnosis
The original criteria for dopamine supersensitivity psychosis were the following:[1]
- A. Continuous use of antipsychotics for at least 3 months.
- B. One of the following:
- 1. Rebound psychosis within 6 weeks of a change (e.g. dose reduction, or antipsychotic switching) in an oral antipsychotic regimen or 3 months for long-acting injectable antipsychotics
- 2. Tolerance to antipsychotic effects (requiring escalating doses, even beyond what has controlled symptoms in the past)
- 3. Presence of tardive dyskinesia (which should occur when antipsychotics are withdrawn, and improve or disappear when antipsychotics are restarted)
Differential diagnosis
It may sometimes be impossible to distinguish dopamine supersensitivity psychosis from psychosis that occurs "naturally" in the course of a primary psychotic disorder like schizophrenia, including cases in which the person was not taking their antipsychotic medication.[1] Even in the presence of an alternative etiology, or when it is impossible to determine the precise etiology for a psychotic episode, it is possible that dopamine supersensitivity psychosis can play a role in the presentation.[1] Recognizing the possible role of dopamine supersensitivity psychosis in a psychotic episode has implications for how to best manage someone's antipsychotic therapy.[1]
History
When supersensitivity psychosis was explored in 1978,[6] a featured concern was increasing resistance to medication, requiring higher doses or not responding to higher doses. Some articles use the term tardive psychosis to reference to this specific concept.[7] However, articles have disputed its validity.[7][8] The condition has been discovered in very few people.[7][9] Palmstierna asserts that tardive psychosis is a combination of "several different and not necessarily correlated phenomena related to neuroleptic treatment of schizophrenia."[7]
Society and culture
Dopamine supersensitivity is often dismissed as an inconsequential factor in the progression of psychotic disorders by
Research
As of 2017[update], much of the evidence for dopamine supersensitivity psychosis comes from studies performed in animals. There is still a need for robust, human research.[2]
In a cohort study of people taking chronic antipsychotic therapy with either schizophrenia or schizoaffective disorder that presented for psychiatric care due to a relapse of their psychotic symptoms without a clear precipitating cause (e.g. new or worsening substance abuse, evidence of nonadherence to antipsychotics), 39% of the sample met the authors' checklist for dopamine supersensitivity psychosis. The people that met the criteria were more likely than others to have worse symptoms when their psychosis returned (relapsed), have residual psychotic symptoms, had overall worse health outcomes at 6-month follow-ups, and were more likely to live in residential care.[14]
Further reading
- Chouinard G, Jones BD (1980). "Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics". Am J Psychiatry. 137 (1): 16–21. PMID 6101522.
- Steiner W, Laporta M, Chouinard G (1990). "Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder". S2CID 36082613.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - Moncrieff J (2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatr Scand. 114 (1): 3–13. S2CID 6267180.
- Miller R, Chouinard G (1993). "Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia". Biol Psychiatry. 34 (10): 713–38. S2CID 2405709.
Notes
- ^ Whitaker's book, a New York Times bestseller, discusses the work of Chouinard and Jones in the section "Supersensitivity Psychosis". Whitaker comments that "In the late 1970s, two physicians at McGill University, Guy Chouinard and Barry Jones, stepped forward with a biological explanation for why the drugs made schizophrenia patients more biologically vulnerable to psychosis". Paraphrasing their work he says: "The severe relapse suffered by many patients withdrawn from antipsychotics was not necessarily the result of the "disease" returning, but rather was drug-related", and "In short, initial exposure to neuroleptics put patients onto a path where they would likely need the drugs for life."[10]
This book was reviewed in New York Review of Books.[13]
References
- ^ S2CID 1957881.
- ^ PMID 27264948.
- ^ PMID 20560996.
- ^ PMID 24904434.
- ^ Katzung, BG; Kruidering-Hall, M; Trevor, AJ (eds.). "Chapter 29: Antipsychotic Agents & Lithium". Katzung & Trevor's Pharmacology: Examination & Board Review (12 ed.). McGraw-Hill.
- PMID 30291.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - ^ S2CID 29048614.
- S2CID 29597822.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - S2CID 38211914.
- ISBN 9780307452429.
- ^ Fitzpatrick, Laura (3 May 2010). "Book review: Anatomy of an Epidemic by Robert Whitaker". Time.
- ^ "Are Psychiatric Medications Making Us Sicker?". Scientific American.
- New York Review of Books.
- PMID 23983951.